RUNBEN BIOTECHNOLOGY (603193.SS)
CNY 33.48
(7.48%)
CNY 33.48
(7.48%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | 252.52 Million | 165.32 Million | 138.65 Million | 87.13 Million | 61.91 Million |
| Net Income | 226.02 Million | 160.04 Million | 120.64 Million | 94.71 Million | 35.67 Million |
| Depreciation & Amortization | 21.86 Million | 19.76 Million | 10.53 Million | 8 Million | 8.01 Million |
| Deferred income taxes | -6.15 Million | -8.7 Million | -3.18 Million | -269.4 Thousand | - |
| Stock-based compensation | - | - | - | - | - |
| Change in working capital | 15.31 Million | -14.88 Million | 4.02 Million | -15.36 Million | 10.44 Million |
| Other non-cash items | -13.75 Million | 396.55 Thousand | 3.44 Million | -218.17 Thousand | 7.78 Million |
| Investing Cash Flow | -1.3 Billion | 9.53 Million | -164.13 Million | -74.98 Million | -42.31 Million |
| Investments in PPE | -13.65 Million | -40.65 Million | -152.03 Million | -58.2 Million | -18.49 Million |
| Acquisitions | 1320.00 | 0.48 | 0.54 | 0.85 | - |
| Investment purchases | -1.88 Billion | -432.62 Million | -431.26 Million | -211.53 Million | -138.01 Million |
| Sales/Maturities of investments | 586.07 Million | 482.66 Million | 419.15 Million | 194.75 Million | 114.18 Million |
| Other Investing Activities | 1320.00 | 138.7 Thousand | 3000.00 | - | 0.21 |
| Financing Cash Flow | 972.84 Million | -9.38 Million | 188.38 Million | 16.25 Million | -11.65 Million |
| Debt repayment | - | - | - | - | - |
| Dividends payments | - | -3.43 Million | -30.95 Million | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | -20.3 Million | - | - | - | - |
| Other Financing Activities | 972.84 Million | -5.94 Million | 219.34 Million | 16.25 Million | -11.65 Million |
| Accounts receivables | 10.37 Million | -2.43 Million | -6.44 Million | -1.97 Million | - |
| Accounts payables | 3.71 Million | 43.2 Million | 27.73 Million | 3.31 Million | - |
| Inventory | 7.38 Million | -46.94 Million | -14.08 Million | -16.43 Million | 4.37 Million |
| Other working capital | -2.44 Million | -8.7 Million | -3.18 Million | -269.27 Thousand | 6.06 Million |
| Cash at beginning of period | 368.14 Million | 202.67 Million | 39.52 Million | 11.11 Million | 3.17 Million |
| Cash at end of period | 283.82 Million | 368.14 Million | 202.67 Million | 39.52 Million | 11.11 Million |
| Capital Expenditure | -13.65 Million | -40.65 Million | -152.03 Million | -58.2 Million | -18.49 Million |
| Effect of forex changes on cash | - | 0.27 | 242.83 Thousand | - | - |
| Net cash flow / Change in cash | -84.32 Million | 165.47 Million | 163.14 Million | 28.4 Million | 7.94 Million |
| Free Cash Flow | 238.86 Million | 124.67 Million | -13.38 Million | 28.93 Million | 43.41 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 80.85 Million | 144.55 Million | 35.47 Million | 45.29 Million | 226.02 Million | 61.26 Million |
| Depreciation & Amortization | - | 5.24 Million | 5.24 Million | - | 21.86 Million | - |
| Deferred income taxes | - | - | - | - | -6.15 Million | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | - | - | - | 15.31 Million | - |
| Other non-cash items | -40.83 Million | 49.49 Million | -63.64 Million | 21.34 Million | -13.75 Million | -61.26 Million |
| Investing Cash Flow | -168.15 Million | 39.74 Million | -150.38 Million | -1.21 Billion | -1.3 Billion | -10.94 Million |
| Investments in PPE | -37.08 Million | -6.22 Million | -1.97 Million | -2.52 Million | -13.65 Million | -1.15 Million |
| Acquisitions | - | - | - | 1320.00 | 1320.00 | 0.31 |
| Investment purchases | -343.1 Million | -354.25 Million | -169.04 Million | -1.66 Billion | -1.88 Billion | -56.18 Million |
| Sales/Maturities of investments | 212.04 Million | 400.22 Million | 20.62 Million | 455.72 Million | 586.07 Million | 46.39 Million |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | -379.76 Thousand | -74.11 Million | -379.76 Thousand | 976.96 Million | 972.84 Million | -2.57 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | -68.78 Million | -68.78 Million | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 4.95 Million | -4.95 Million | - | -20.3 Million | -20.3 Million | - |
| Other Financing Activities | -379.76 Thousand | 379.76 Thousand | -379.76 Thousand | 976.96 Million | 972.84 Million | -2.57 Million |
| Accounts receivables | - | - | - | - | 10.37 Million | - |
| Accounts payables | - | - | - | - | 3.71 Million | - |
| Inventory | - | - | - | - | 7.38 Million | - |
| Other working capital | - | - | - | - | - | - |
| Cash at beginning of period | 259.17 Million | 104.73 Million | 283.82 Million | 458.34 Million | 368.14 Million | 409.7 Million |
| Cash at end of period | 129.4 Million | 259.17 Million | 104.73 Million | 283.82 Million | 283.82 Million | 458.34 Million |
| Capital Expenditure | -37.08 Million | -6.22 Million | -1.97 Million | -2.52 Million | -13.65 Million | -1.15 Million |
| Effect of forex changes on cash | -306.18 | - | - | - | - | - |
| Net cash flow / Change in cash | -129.76 Million | 154.43 Million | -179.08 Million | -174.51 Million | -84.32 Million | 48.64 Million |
| Free Cash Flow | 2.92 Million | 182.58 Million | -30.14 Million | 64.11 Million | 238.86 Million | -1.15 Million |
HONASA
603991
AVAP
FPP
MAS
MIRI